Abstracts

420 – Molecular Mechanisms Underlying Anti-HIV-1 Fc-Effector Functions of Human IgA Allelic Variants

Background IgA is the most abundant antibody in humans, yet its function in viral infections, including HIV-1, is elusive. Humans have two IgA subclasses: IgA1 (with 1 allelic variant) and IgA2 (with 3 allelic variants), differing in sequence, hinge length, and glycosylation, and expressed as monomers (mIgA), dimers (dIgA), or secretory forms (sIgA). Neutralization at…

1358 – Regional Disparities in DoxyPEP Uptake Despite High Awareness Among MSM With HIV in the US

Background The CDC recently issued guidelines recommending doxycycline post-exposure prophylaxis (doxyPEP) for men who have sex with men (MSM) who have had a bacterial sexually transmitted infection (bSTI) in the past year. However, this strategy remains underutilized among some groups. The primary objective of this study was to explore doxyPEP use, prescription within participants’ primary…

355 – Residual HIV Viremia Associates With Reservoir Size, but Not With Immune Activation or Inflammation

Background Plasma viral loads (VL) in persons with HIV (PWH) taking antiretroviral therapy are generally below the limit of quantification. However, commercial PCR tests differentiate between unquantifiable low, but detectable VL (<40 c/ml, residual viremia, RV) and Target Not Detected (TND). Whether RV drives or is driven by systemic immune activation remains debated. Large studies…

1315 – Capacity for PrEP Implementation at Pharmacies in Baltimore and San Diego: A Mixed-Methods Study

Background HIV pre-exposure prophylaxis (PrEP) uptake remains disproportionately low among communities with the highest HIV incidence in the US due to stigma, structural inequities, limited access, and long wait times. Pharmacy-initiated PrEP could dramatically expand access, but pharmacy capacity for PrEP delivery has been understudied. Current legislation allows pharmacy-initiated PrEP in 10 states (including California) but has…

1277 – Characteristics of Breakthrough Chlamydia Cases Among Cisgender Women Assigned to Doxycycline PEP

Background Doxycycline postexposure prophylaxis (PEP), taken within 72 hours of condomless sexual exposure, did not reduce incident bacterial STIs among cisgender women in the only trial conducted to date; use of doxycycline PEP in that trial was low. Methods We describe 35 breakthrough cases of incident Chlamydia trachomatis among 32 participants assigned to doxycycline PEP…